NCT05361720View on ClinicalTrials.gov

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

July 1, 2026

Conditions
Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
DRUG

Cabozantinib

Given PO

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (6)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

44106

RECRUITING

University Hospitals Seidman Cancer Center, Cleveland

44195

RECRUITING

Cleveland Clinic, Cleveland

75390

RECRUITING

University of Texas, Southwestern Medical Center, Dallas

91010

RECRUITING

City of Hope National Medical Center, Duarte

92868

RECRUITING

Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

United States Department of Defense

FED

lead

Vanderbilt-Ingram Cancer Center

OTHER